SpecificationsOrganism/cell line/tissue*Homo sapiens*/ER-positive MCF-7 breast cancer cell lineSexFemaleSequencer or array typeAgilent\'s human gene expression study 8 × 60 K microarray slides (AMADID:27114)Data formatRaw and processedExperimental factorsMCF-7 cells treated with 17β-estradiol, EGCG or both.Experimental featuresTotal RNA samples isolated from MCF-7 cells treated with 17β-estradiol (10 nM), EGCG (40 μM) or both for a period of 24 h were subjected to microarray analysis using the Agilent platform. Total RNA from cells treated with ethanol (vehicle) served as controls. Eight hybridizations (one color) with eight total RNA samples were carried out. These comprised of total RNA samples from two experimental replicates each of 17β-estradiol, EGCG, 17β-estradiol + EGCG, and ethanol treated cells.ConsentN/ASample source locationGuwahati, Assam, India

1. Direct link to deposited data {#s0005}
================================

[http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE56245](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56245){#ir0005}.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Cell culture {#s0015}
-----------------

The ER-positive human breast cancer cell line, MCF-7, was routinely cultured in 25 cm^2^ flasks (Greiner Bio-One, GmbH, Germany), under standard culture conditions (37 °C, 5% CO~2~), in phenol red containing DMEM-F12 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 units/ml of penicillin and 100 μg/ml of streptomycin (M1). Once confluent, the cells were trypsinized and split into fresh 25 cm^2^ flasks in a ratio of 1:3 for expansion. Else, the cells were seeded in 35 mm dishes (2 × 10^5^ cells per dish) using M1 for experimentation.

2.2. Experimental protocol {#s0020}
--------------------------

Once the 35 mm dishes were 60--70% confluent, M1 was replaced with phenol red-free DMEM-F12 supplemented with 10% charcoal stripped heat-inactivated FBS, 100 units/ml of penicillin and 100 μg/ml of streptomycin (M2), and allowed to grow for 4 h. Spent M2 was then replaced with fresh M2 containing ethanol (vehicle), 10 nM of 17β-estradiol (E2), 40 μM of EGCG, or both and incubated further for a period of 24 h before harvesting the cells for total RNA extraction. Thus, the experiment comprised of four treatment groups including the vehicle control. Two dishes (biological replicates for the microarray analysis) were assigned for each of the treatment groups. The concentrations of E2 and EGCG were optimized earlier [@bb0005]. The effectiveness of 10 nM of E2 was confirmed based on the induction of steady state mRNA levels of two estrogen induced genes, namely trefoil factor-1 (pS2) and progesterone receptor (PR). EGCG at 40 μM concentration was ideally suited for this experiment, since it caused only a modest (20%) reduction in viability of MCF-7 cells. Under this condition the modulation in gene expression by EGCG could safely be interpreted as primary, and not as a collateral effect of cyotoxicity observed at high concentrations [@bb0005].

At the end of the experiment, the cells were lysed in RLT buffer (RNeasy kit, Qiagen, GmbH, Germany). Lysates were sent to Genotypic Technology (P) Ltd., Bangalore, India for total RNA extraction, labeling, hybridization, image acquisition, quality control and primary analysis of raw intensity data.

2.3. RNA isolation, labeling, hybridization and image acquisition {#s0025}
-----------------------------------------------------------------

RNeasy Mini Kit (Qiagen, GmbH, Germany) was used to extract total RNA. RNA concentrations were determined based on absorbance at 260 nm wavelength of light. The quality of RNA was assessed on 2100 Bioanalyzer (Agilent, Paulo Alto, CA, USA). RNA samples were considered to be of good quality if they satisfied the following criteria --- a) A260/A280 ratio \> 1.8, b) A260/A230 ratio ≥ 1.5, and c) 28S/18S intensity ratio \> 1.5. All our total RNA samples satisfied these criteria. The RNA quality control data are provided in [Table 1](#t0005){ref-type="table"}.

For each sample, 500 ng of total RNA was labeled (one color with Cy3) using Agilent\'s Low Input RNA linear amplification kit (Cat No. 5188--5339). The labeled complementary RNAs were purified using RNeasy Mini Kit, checked for quality ([Table 2](#t0010){ref-type="table"}) and hybridized to Agilent\'s human gene expression study 8 × 60 K microarray slides (AMADID:27,114), using the Agilent\'s in situ hybridization kit (Cat No. 5184--3568). Following hybridization and washes, the images were scanned in microarray scanner (Model G2565BA, Agilent). The raw intensity data was extracted using Agilent\'s Feature Extraction Software.

2.4. Assessment of image quality {#s0030}
--------------------------------

The images were manually checked for uneven hybridizations, streaks, blobs and other artifacts. Images were found to be clean with low background noise. Microarray images and signal statistics for each array are provided as supplementary information in Appendices A and B, respectively.

2.5. Microarray data analysis {#s0035}
-----------------------------

For data analysis we used LIMMA package from Bioconductor [@bb0010]. Background correction was performed using "normexp" method in LIMMA with an offset of 16 [@bb0015]. The "quantile" method was used for normalization of the data between arrays. Further, the "avereps" function was used to average replicate spots. We applied "lmfit" (linear model) and "eBayes" (Empirical Bayes method) for determination of differentially regulated genes. The R code used for processing of the data is as follows:

Library (limma)

Targets = readTargets("targets.txt")

x = read.maimages(targets, source ="agilent", green.only = TRUE)

y = backgroundCorrect(x, method ="normexp", offset = 16)

y = normalizeBetweenArrays(y, method ="quantile")

y.ave = avereps(y, ID = y\$genes\$ProbeName)

f = factor(targets\$Condition, levels = unique(targets\$Condition))

design = model.matrix(\~ 0 + f)

colnames(design)=levels(f)

fit = lmFit(y.ave, design)

contrast.matrix = makeContrasts("E-C", "X-C", "EX-C", levels = design)

fit2 = contrasts.fit(fit, contrast.matrix)

fit2 = eBayes(fit2)

output = toptable(fit2, adjust ="BH", coef ="E-C", genelist = y.ave\$gene, number = Inf)

write.table(output, file ="E-C.txt", sep ="\\t", quote = FALSE)

output1 = toptable(fit2, adjust ="BH", coef ="X-C", genelist = y.ave\$gene, number = Inf)

write.table(output1, file ="X-C.txt", sep ="\\t", quote = FALSE)

output2 = toptable(fit2, adjust ="BH", coef ="EX-C", genelist = y.ave\$gene, number = Inf)

write.table(output2, file ="EX-C.txt", sep ="\\t", quote = FALSE).

3. Discussion {#s0040}
=============

An inverse correlation between green tea consumption and breast cancer risk is apparent from the results of epidemiological studies [@bb0020], [@bb0025], [@bb0030]. The widespread interest in the major green tea polyphenol, EGCG, as a chemopreventive and chemotherapeutic agent against breast cancer stems from a substantial amount of data available through experimental studies using cell culture and animal models of breast carcinogenesis [@bb0035], [@bb0040], [@bb0045], [@bb0050]. Molecular targets of EGCG have also been identified [@bb0055]. However, despite the fact that majority of breast tumors at diagnosis are estrogen dependent and ER positive, the impact of EGCG on estrogen mediated cellular processes and global gene expression has not been addressed.

Taking a cue from earlier studies which suggest that EGCG can influence estrogen regulated gene expression [@bb0060], [@bb0065], [@bb0070], [@bb0075], we also demonstrated EGCG mediated increase in mRNA levels of the two estrogen induced transcripts, namely pS2 and PR [@bb0005]. The microarray experiment described in this report seeks to address the impact of EGCG on estrogen regulated gene expression at the genome-wide scale. The results of the basic analysis of differentially expressed genes by the treatments with respect to control are presented in [Table 3](#t0015){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}. While on one hand there are genes exclusively modulated by each of the treatments, on the other hand a considerable overlap of genes between the treatment groups is also apparent from the data.

This work and the resulting data is a small but significant step towards understanding the mechanism of EGCG action. A comprehensive analysis of the microarray data generated in this study will be useful in obtaining insights into EGCG mediated modulation of estrogen driven processes in ER-positive breast cancer cells. This in turn will help in judging the true potential of EGCG as a chemopreventive or chemotherapeutic agent against breast cancer.
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![Venn diagram showing the number of probes regulated by the indicated treatments. The concentrations used are 10 nM for E2 and 40 μM for EGCG.](gr1){#f0005}

###### 

Total RNA quality control.

  Sample codes[a](#tf0005){ref-type="table-fn"}   Absorbance value 260/280   Absorbance value 260/230   RNA concentration (ng/μl)   Total yield (ng)   QC purity   **QC conc./yield**   QC integrity
  ----------------------------------------------- -------------------------- -------------------------- --------------------------- ------------------ ----------- -------------------- --------------
  C1                                              2.1                        2.2                        324.3                       6485.6             Optimal     Optimal              Good
  C2                                              2.1                        1.5                        260.1                       5202.6             Optimal     Optimal              Good
  E1                                              2.1                        2.2                        336.3                       6726.0             Optimal     Optimal              Good
  E2                                              2.1                        2.2                        337.4                       6747.6             Optimal     Optimal              Good
  X1                                              2.1                        2.2                        359.1                       7182.6             Optimal     Optimal              Good
  X2                                              2.1                        2.2                        410.2                       8204.2             Optimal     Optimal              Optimal
  EX1                                             2.1                        1.9                        283.6                       5671.0             Optimal     Optimal              Good
  EX2                                             2.1                        2.2                        338.7                       6773.6             Optimal     Optimal              Good

C1 & C2---vehicle treated, E1 & E2---10 nM of 17β-estradiol, X1 & X2---40 μM of EGCG, EX1 & EX2---combined treatment with the 10 nM of 17β-estradiol and 40 μM of EGCG.

###### 

Quality control of Cy3 incorporation in the labeled RNA.

  Sample codes[a](#tf0010){ref-type="table-fn"}   Cy3 (pmol/μl)   Concentration of labeled RNA (ng/μl)   Absorbance 260/280   Specific activity pmol dye/μg cRNA
  ----------------------------------------------- --------------- -------------------------------------- -------------------- ------------------------------------
  C1                                              1.67            167.56                                 2.26                 9.97
  C2                                              1.02            115.87                                 2.34                 8.80
  E1                                              1.80            176.40                                 2.28                 10.20
  E2                                              1.83            165.75                                 2.28                 11.04
  X1                                              2.25            196.64                                 2.29                 11.44
  X2                                              2.16            202.70                                 2.31                 10.66
  EX1                                             2.01            193.02                                 2.35                 10.41
  EX2                                             1.08            126.66                                 2.34                 8.53

C1 & C2---vehicle treated, E1 & E2---10 nM of 17β-estradiol, X1 & X2---40 μM of EGCG, EX1 & EX2---combined treatment with the 10 nM of 17β-estradiol and 40 μM of EGCG.

###### 

A summary of number of probes modulated by E2, EGCG and both.

  Treatment[a](#tf0015){ref-type="table-fn"}   Total number of probes showing modulation[b](#tf0020){ref-type="table-fn"}   Number of probes showing induction   Number of probes showing repression
  -------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------ -------------------------------------
  E2                                           3411                                                                         1689                                 1722
  EGCG                                         3317                                                                         1844                                 1473
  E2 + EGCG                                    9183                                                                         4998                                 4185

The concentrations used are 10 nM for E2 and 40 μM for EGCG.

The number of probes showing modulation with respect to vehicle treated control.
